Literature DB >> 16309224

E-cadherin and beta-catenin expression in normal, inflamed and cancerous gallbladder tissue.

Harald Puhalla1, Beate Herberger, Afschin Soleiman, Martin Filipits, Fritz Laengle, Thomas Gruenberger, Fritz Wrba.   

Abstract

BACKGROUND: Changes of the E-cadherin/beta-catenin complex during cell-cell interactions result in the loss of cell adhesion and may account for the ability of cancer cells to metastasize. Gallbladder carcinoma (GBC) can develop during chronic inflammation from normal tissue. The aim of this study was to investigate the expression of E-cadherin and beta-catenin in normal gallbladder mucosa, inflamed gallbladder tissue and GBC.
MATERIALS AND METHODS: Tissue from 10 GBC, 10 chronic cholecystitis and 10 healthy gallbladders were used to evaluate the expression of E-cadherin and beta-catenin by immunohistochemistry.
RESULTS: The beta-catenin membranous expression decreased between cholecystitis and malignant tissue, as well as between normal epithelium and carcinoma. The E-cadherin membranous expression was reduced in normal gallbladder epithelia compared to carcinoma and also from inflammation to GBC. The cytoplasmatic beta-catenin expression did not show any significant difference. Cytoplasmatic E-cadherin was significantly different from normal gallbladders to carcinomas and between normal tissue and inflammation. No significant difference of the nuclear P-catenin expression could be observed. E-cadherin was not detected intra-nuclear in any tissue.
CONCLUSION: Significant differences of E-cadherin and beta-catenin were detected between normal, inflamed and cancerous tissues. These changes of the protein expressions and the associated loss of adhesive mechanisms might lead to a cancerous pathway in GBC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309224

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Role of E-cadherin gene in gall bladder cancer and its precursor lesions.

Authors:  T Padma Priya; V K Kapoor; N Krishnani; Vinita Agrawal; Suraksha Agrawal
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

Review 2.  Regulation of EMT by KLF4 in gastrointestinal cancer.

Authors:  Jiujie Cui; Min Shi; Ming Quan; Keping Xie
Journal:  Curr Cancer Drug Targets       Date:  2013-11       Impact factor: 3.428

Review 3.  Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks.

Authors:  Sunwang Xu; Ming Zhan; Jian Wang
Journal:  Cell Death Discov       Date:  2017-11-27

4.  Melatonin inhibits gallbladder cancer cell migration and invasion via ERK-mediated induction of epithelial-to-mesenchymal transition.

Authors:  Hongwei Tang; Xiaoyi Shi; Pengfei Zhu; Wenzhi Guo; Jie Li; Bing Yan; Shuijun Zhang
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

5.  p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer.

Authors:  Mila Ghosh; Puja Sakhuja; Shivendra Singh; Anil K Agarwal
Journal:  Saudi J Gastroenterol       Date:  2013 Jan-Feb       Impact factor: 2.485

6.  Molecular biology of gallbladder cancer: potential clinical implications.

Authors:  Ake Andrén-Sandberg
Journal:  N Am J Med Sci       Date:  2012-10

7.  Interleukin 17A promotes gallbladder cancer invasiveness via ERK/NF-κB signal pathway mediated epithelial-to-mesenchymal transition.

Authors:  Kunlun Chen; Hongwei Tang; Pengfei Zhu; Jianwen Ye; Dong Liu; Yansong Pu; Lei Zhang; Wenlong Zhai
Journal:  J Cancer       Date:  2020-05-18       Impact factor: 4.207

8.  Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway.

Authors:  Kaushik Neogi; Prashant R Murumkar; Priyanshu Sharma; Poonam Yadav; Mallika Tewari; Devarajan Karunagaran; Prasanta Kumar Nayak; Mange Ram Yadav
Journal:  Transl Oncol       Date:  2022-03-21       Impact factor: 4.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.